Table 1. Relationship between IGF2BP3 expression and clinicopathological features in HCC tissues.
| Clinicopathological Features | Number of cases | IGF2BP3 immunostaining# | ||
|---|---|---|---|---|
| Score 0 N (%) |
Score 1 N (%) |
P Value | ||
| Age (years) | ||||
| <60 | 159 | 97 (69.29) | 62 (65.26) | 0.518 |
| ≥60 | 76 | 43 (30.71) | 33 (34.74) | |
| Gender | ||||
| Male | 190 | 109 (77.86) | 81 (84.38) | 0.214 |
| Female | 46 | 31 (22.14) | 15 (15.62) | |
| Tumor size | ||||
| ≤5 cm | 113 | 66 (47.83) | 47 (51.65) | 0.571 |
| >5 cm | 116 | 72 (52.17) | 44 (48.35) | |
| AFP (ng/ml) | ||||
| ≤20 | 79 | 51 (37.5) | 28 (29.17) | 0.187 |
| >20 | 153 | 85 (62.5) | 68 (70.83) | |
| HBV infection | ||||
| Negative | 42 | 28 (20.74) | 14 (14.89) | 0.261 |
| Positive | 187 | 107 (79.26) | 80 (85.11) | |
| Cirrhosis | ||||
| Absent | 38 | 25 (17.86) | 13 (13.54) | 0.376 |
| Present | 198 | 115 (82.14) | 83 (86.46) | |
| Edmondson's grade | ||||
| I, II | 119 | 78 (55.71) | 41 (42.71) | 0.050* |
| III, IV | 117 | 62 (44.29) | 55 (57.29) | |
| Intrahepatic metastasis | ||||
| Absent | 161 | 105 (75.00) | 56 (58.33) | 0.007* |
| Present | 75 | 35 (25.00) | 40 (41.67) | |
AFP, alpha-fetoprotein. N, Number of cases. p value represents the probability from a Chi-square test for different immunohistochemical scores of IGF2BP3 in HCC tissues.
*
p < 0.05.
#
Score 0 and Score 1 respectively indicate weak and strong immunostaining.